Bayer Stock News

LEVERKUSEN, Germany--(BUSINESS WIRE)--The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company's Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company's Chief Financial Officer (CFO) on June 1, 2026, following his planned retirement at the end of May 2026. Dr. Hartmann is currently an Operating Partner at Sandbrook Capital, a priv...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented in scientific sessions at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas, November 6–9. “Up to 30% of Americans living with type 1 diabetes (T1D) are affected by chronic kidney disease (CKD),1,2 which puts the...

Bayer DE000BAY0017 hat in den US-Rechtsstreitigkeiten rund um die schon seit Jahrzehnten verbotene Umweltchemikalie PCB einen Rückschlag hinnehmen müssen.

The ‘Take Care, Now' Campaign Has Helped Provide 10 Million Meals to Families in Need Through Feeding America The ‘Take Care, Now' Campaign Has Helped Provide 10 Million Meals to Families in Need Through Feeding America

Bayer DE000BAY0017 hat in den USA die Zulassung für seinen Menopause-Wirkstoff Elinzanetant erhalten.

Germany's Bayer said on Friday the U.S. Food and Drug Administration has approved its drug for menopause relief.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokinin B through an...

Bayer DE000BAY0017 hat in den USA die Zulassung für sein Menopause-Mittel Elinzanetant erhalten.